ncRNA basic information
ncRNA ID:
MIMAT0000275
ncRNA Database:
miRBase
ncRNA Name:
miR-218-5p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
PRKCE
ncRNA Pathway:
PRKCE/MDR1 pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00441 (APRD00201)
Drug Name:
Gemcitabine
Drug Method:
In this study, we show that miR-218-5p plays a critical role in gemcitabine resistance of GBC. miR-218-5p levels were significantly lower in GBC than adjacent non-cancer tissues, and which were also associated with patient prognosis. While miR-218-5p overexpression abrogated gemcitabine resistance of GBC cells, silencing of which exhibited the opposite effects. Via six microRNA targets prediction algorithms, we found that PRKCE is a potential target of miR-218-5p. Moreover, miR-218-5p overexpression repressed the luciferase activity of reporter constructs containing 3-UTR of PRKCE and also reduced PRKCE expression. Further studies revealed that miR-218-5p promotes sensitivity of gemcitabine by abolishing PRKCE-induced upregulation of MDR1/P-gp. Taken together, our results imply that an intimate correlation between miR-218-5p and PRKCE/MDR1 axis abnormal expression is a key determinant of gemcitabine tolerance, and suggest a novel miR-218-5p-based clinical intervention target for GBC patients.
Drug Response:
sensitive
Cancer basic information
Cancer:
gallbladder cancer
Tissue/Cell:
cell line (GBC-SD,SGC-996,NOZ)
Other information
Title:
miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.
Journal:
Cell Death Dis
Published:
2017
PubMed ID:
28492560